PHARMAC responds on tolterodine for overactive bladder.
Peter
P
Moodie
D001559:Benzhydryl Compounds / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003408:Cresols / Q000191:economics / Q000627:therapeutic use*; D004341:Drug Evaluation; D033161:Government Regulation; D006801:Humans; D018727:Muscarinic Antagonists / Q000191:economics / Q000627:therapeutic use*; D009520:New Zealand; D010665:Phenylpropanolamine / Q000191:economics / Q000627:therapeutic use*; D000068737:Tolterodine Tartrate; D014549:Urinary Incontinence / Q000188:drug therapy*
D001559:Benzhydryl Compounds; D003408:Cresols; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate